
    
      The planned length of participation in the study for each subject is up to approximately 110
      weeks (from screening through completion of follow-up). This includes:

        -  Screening/baseline period of up to 4 weeks

        -  Double-blind, placebo-controlled treatment period of 48 weeks

        -  Open-label extension treatment period of 48 weeks ( all subject to enter a 48-week open
           label extension period and receive active treatment with lademirsen (SAR339375))

        -  Post-treatment follow-up period of 10 weeks
    
  